Douglas Melamed

Doug Melamed is Professor of the Practice of Law at Stanford Law School.  He joined the Stanford faculty in 2014.  In the Fall of 2017, he was the Florence Rogatz Visiting Professor in the Practice of Law at Yale Law School.

From 2009 until 2014, Doug was Senior Vice President and General Counsel of Intel Corporation and was responsible for overseeing Intel’s legal, government affairs, and corporate affairs departments. Prior to joining Intel in 2009, he was a partner in the Washington, D.C., office of WilmerHale, a global law firm in which he served as a chair of the Antitrust and Competition Practice Group.  From 1996 to 2001, he served in the U.S. Department of Justice as Acting Assistant Attorney General in charge of the Antitrust Division and, before that, as Principal Deputy Assistant Attorney General.

Doug has authored numerous articles on antitrust, patent law, and law and economics. He is a member of the American Law Institute and a Contributing Editor of the Antitrust Law Journal and a former member of the boards of directors of the Nasdaq exchanges.  Doug received his B.A. from Yale and his J.D. from Harvard, where he was an editor of the Harvard Law Review.

When AI Helps Generate Inventions, Who Is the Inventor?

By Andrei Iancu and Rama Elluru This commentary from the CSIS-SCSP Task Force on IP in the AI Era was originally published in the Special Competitive Studies Project’s Substack on February 15, 2024. With roots in the U.S. constitution, patent rights provide an exclusive property right in new inventions like drugs,
Read More

Standard Essential Patents and European Economic Security

By Kirti Gupta and Chris Borges On April 27, 2023, the European Commission published a draft proposal on standard essential patents (SEPs) seeking to address the perceived lack of transparency and predictability in the licensing of SEPs. The commission proposes the creation of a competence center within the European Union Intellectual
Read More

Proposed Federal Use of March-in Rights Would Weaken American Innovation

By Sujai Shivakumar and Thomas Howell   The Biden administration is considering exercising something called “march-in rights” as a policy prescription to curb drug prices. But as with any prescription, there is a need to weigh efficacy against the side-effects. In this case, there is evidence that the vast majority of
Read More